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REVIEW
More than sugar in the milk: human milk oligosaccharides as essential bioactive
molecules in breast milk and current insight in beneficial effects
Lianghui Chenga , Renate Akkermana, Chunli Konga, Marthe T. C. Walvoortb, and Paul de Vosa
aImmunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands; bStratingh Institute for Chemistry, Faculty of Science and Engineering, University of
Groningen, Groningen, Netherlands
ABSTRACT
Human milk is the gold standard for newborn infants. Breast milk not only provides nutrients, it
also contains bioactive components that guide the development of the infant’s intestinal immune
system, which can have a lifelong effect. The bioactive molecules in breast milk regulate micro-
biota development, immune maturation and gut barrier function. Human milk oligosaccharides
(hMOs) are the most abundant bioactive molecules in human milk and have multiple beneficial
functions such as support of growth of beneficial bacteria, anti-pathogenic effects, immune modu-
lating effects, and stimulation of intestine barrier functions. Here we critically review the current
insight into the benefits of bioactive molecules in mother milk that contribute to neonatal devel-
opment and focus on current knowledge of hMO-functions on microbiota and the gastrointestinal
immune barrier. hMOs produced via genetically engineered microorganisms are now applied in
infant formulas to mimic the nutritional composition of breast milk as closely as possible, and their








It is widely accepted that breastfeeding is the gold standard
for infant nutrition. It offers complete nutrition for the new-
born as well as many bioactive components that contribute
to healthy development of the newborn (Doare et al. 2018).
These bioactive molecules can shape microbiota compos-
ition, modulate gastrointestinal physiology, promote proper
development of the immune system, and enhance intestinal
barrier function (Gila-Diaz et al. 2019). Many studies have
focused on understanding the composition of mother milk
and on identifying which factors contribute to healthy devel-
opment of the child. This knowledge is essential for the
development of effective infant formula that until several
years ago was associated which higher frequencies of atopic
allergies, a different microbiota composition, higher risks for
infectious diseases, higher rates of obesity, and even higher
frequency of diabetes when compared to children solely fed
on mother milk (Binns, Lee, and Low 2016; Doare et al.
2018; Lodge et al. 2015). Effective formulations will have a
profound impact on child health, as over 70% of all infants
receive infant formula, and thereby depend on cow milk-
based infant formulas for daily supply of nutrients and
bioactive components (Victora et al. 2016). These cow milk-
derived infant formulas do not have the same bioactive mol-
ecules as human milk (Aly et al. 2018).
The intestinal tract is the first organ that is in contact
with bioactive molecules in mother milk. In the infant’s
intestine the bioactive milk components impact the imma-
ture intestinal mucosa, which contains more than 80% of
the body’s immune cells. The cells are matured by the bio-
active factors facilitating the monitoring of luminal food
components across the intestinal barrier and supporting
regulation of defense-responses against undesired intruders.
At the same time the maturation of immune cells supports
regulatory responses to e.g. commensal bacteria that are
needed for host survival (Lewis and Blutt 2019). The muco-
sal immunity is integrated into a physical barrier which is
composed of a mucus layer and closely connected epithelial
cells that protect the host from the harsh luminal content of
the gut (Okumura and Takeda 2017). In newborn infants
this barrier is more diffuse, and the maturation to an intact
barrier is needed to prevent pathogens from entering the
host (Torow et al. 2017). It is assumed that also closing the
barrier is supported by bioactive components in mother
milk (Cacho and Lawrence 2017). In addition, the bioactive
molecules in mother milk support colonization of the more
than 100 trillion microbiota in the small and large intestine
that digest foods and produce fermentation products that
are needed to support our metabolism, immunity and brain
health (Figueroa-Lozano and de Vos 2019; McLeod
et al. 2019).
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There is increasing evidence that bioactive molecules in
human milk have short- and long-term benefits in the devel-
oping intestinal system with impact on the development of
the neonate as a whole (L€onnerdal 2014). These bioactive
molecules involve a large group of compounds, such as
growth factors (Vass et al. 2019), carbohydrates (Coppa
et al. 1993; Nijman et al. 2018), cells (Cregan et al. 2007;
Patki et al. 2010), cytokines (Meki et al. 2003) and immuno-
globulins (Savel’ev et al. 2001). In order to gain insight into
the function of these molecules in maintaining health or
stimulating specific maturation processes, many studies have
focused on comparing the composition of preterm and term
delivered infants. Preterm infants are more prone to inflam-
matory diseases such as necrotizing enterocolitis, and by
comparing preterm milk compositions with term milk com-
positions researchers try to identify essential elements in
milk composition that might lead to novel formulations to
prevent inflammatory events in preterm infants (Boyce et al.
2016; Cappelletti et al. 2016). More than that, over the
course of lactation variations in the composition of mother
milk has been reported, which is considered to be a
response of the mother to the changing needs of the infant.
Not only identifying essential molecules for promoting
health has been a major focus in infant formula research,
finding cost effective means to include the molecules in infant
formula has been a major effort as well, as most molecules
are too complex to produce or are subject to many regulatory
issues (Cicero, Fogacci, and Colletti 2017; Hill and Newburg
2015). Recently, major advances have been made with the
inclusion of human milk oligosaccharides (hMOs) in infant
formula (Vandenplas et al. 2018). hMOs are the most abun-
dant bioactive molecules in human milk (Neu et al. 2019).
Human milk contains more than 200 hMOs which are virtu-
ally absent in cow-milk based formulations (Bode 2012).
Some hMOs that are abundantly present in mother milk can
be produced via genetically engineered microorganisms and
are now applied in infant formulas (Vandenplas et al. 2018).
There is some evidence that this might lead to specific health
benefits compared to traditional infant formulas that are sup-
plemented with non-digestible carbohydrates (Puccio et al.
2017). Some hMOs have multiple functions which include
support of growth of beneficial bacteria, anti-pathogenic
effects, immune modulating effects and stimulating intestine
barrier functions (Cheng et al. 2019; Kong et al. 2019;
Triantis, Bode, and van Neerven 2018). Whether these effects
can be achieved with the addition of single hMO instead of a
mixture of hMOs is currently subject of study (Cheng et al.
2019; Kong et al. 2019; Salli et al. 2019).
In this review, we first briefly discuss the intestinal immun-
ity in the small and large intestine, as most of the barrier
immune effects of bioactive molecules start in the intestinal
tract. Next, we critically review the current insight into the
benefits of bioactive molecules in mother milk, including
growth factors, antimicrobial proteins, cytokines, immunoglo-
bulins, and cells in mother milk, that are all considered to
contribute to neonatal development. The focus of the review
will be on current knowledge of specific structure-activity rela-
tions of hMOs, as the first infant formulas with synthetic
hMOs such as 20-FL have reached the market. We discuss the
impact they may have on microbiota and the gastrointestinal
immune barrier. Finally, we discuss the currently applied
hMOs in infant formula as well as their prospects and scien-
tific challenges in the field of infant nutrition research.
The intestinal immune system
The intestinal mucosa of a healthy adult contains more than
80% of the body’s immune cells, which makes the gastro-
intestinal tract the largest immunologically active organ of
the human body (Lewis and Blutt 2019). Its primary func-
tion is to protect the human body from undesired intruders
from the lumen of the intestine while at the same time
inducing tolerance to the 100 trillion bacteria that are
needed for digestive processes and for production of benefi-
cial fermentation products such as short chain fatty acids
(SCFAs) (Figueroa-Lozano and de Vos 2019; McLeod et al.
2019). The mucosal immune system is integrated into a
physical barrier which is composed of a mucus layer and
closely connected epithelial cells that protect the host from
the harsh luminal content of the gut (Okumura and Takeda
2017). In the small intestine, the mucosal immune system is
highly organized, with fingerlike projections called villi,
whose primary function is absorption of nutrients. It con-
tains unique cells with specialized functions. At the base of
the villi, in the crypts, the intestinal stem cells (ISCs) are
located (Allaire et al. 2018), as well as the so-called Paneth
cells which produce antimicrobial peptides and are respon-
sible for maintaining a healthy balance in microbiota popu-
lations (Jansen 2019). Goblet cells are scattered in between
the epithelial cells located at the villus and secrete gel-form-
ing mucins (Knoop and Newberry 2018). Mucus is the prin-
cipal barrier between the lumen and the underlying
epithelial cells (Boedeker and Allen 2018).
The immune components of the gut-associated lymphoid
tissue (GALT) are localized in microenvironments such as
the Peyer’s patches (PPs), mesenteric lymph nodes (MLNs),
and lamina propria (LP) (Figure 1A). The GALT is a sec-
ondary lymphoid organ that can be divided into an induct-
ive site and an effector site (Brandtzaeg 2016). The
induction site is compartmentalized into the small intestinal
PPs and the MLNs, while the effector site is spread over the
entire region of the intestinal LP (Brandtzaeg 2016). The
small intestinal PPs are lymphoid tissues containing immune
cells. The PPs are partly covered with specialized epithelial
cells called microfold cells (M cells) that sample antigens
from the lumen (Ahmad et al. 2017). The key function of
the PPs is presenting antigens that are sampled by M cells
or dendritic cells which protrude their dendrites into the
lumen and regulate immune responses (Tezuka and Ohteki
2019). Due to this sampling and presentation function, the
PPs are considered to be important for coordination of
immune responses (Mowat and Agace 2014). Moreover, the
PPs contain follicles where B cells are located. Those B cells
secrete IgA which binds and neutralizes pathogens and
undesired food antigens (Reboldi and Cyster 2016). The
antigen presenting cells (APC) present in the PPs, such as
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CD103 positive dendritic cells, can migrate to the MLNs
after uptake of antigens and activate naive lymphocytes
(Tezuka and Ohteki 2019). Some of these cell populations
are regulatory T cells (Treg), which induce tolerance to food
antigens and microbiota, while more undesired antigens,
such as those of pathogens, can induce formation of T
helper (Th) cells (Vojdani 2015).
The large intestine is considered to be a less immuno-
logically active site as compared to the small intestine. In
the large intestine there is less direct contact between the
luminal antigens and molecules and the mucosal immune
system due to a firm mucus layer on top of the epithelial
cells (Figure 1B). The large intestine has no villi, only crypts.
The goblet cell is one of the major cell types of the colonic
crypt, and is responsible for the secretion of gel forming
mucins that provide protection against pathogenic intruders
and supports growth of commensal bacteria (Allaire et al.
2018). Unlike the thinner mucus layer in the small intestine,
that promotes nutrient absorption and antigen sampling, the
large intestine has a two-layered mucus structure (Martens,
Neumann, and Desai 2018). The colonic mucus is organized
in an inner and an outer layer. The inner layer is firmly
Figure 1. The intestinal immune barrier. (A) The small intestinal immune barrier. The mucus and the underlying closely connected epithelial cells form a barrier between
the immune system and luminal content, which contains food and microbiota. Different cells contribute to the maintenance of barrier function and to balancing immune
responses. These include intestinal epithelial cells, M cells, Paneth cells, stem cells and goblet cells. The immune components of the gut-associated lymphoid tissue are
localized in Peyer’s patches, mesenteric lymph nodes, and lamina propria. (B) The large intestine. Colonocytes and goblet cells are the major cell types of the colonic
crypt. Goblet cells produce mucus to form the outer and inner mucus layer which serves as protective barrier. The outer mucus layer harbors the commensal flora.
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adherent to the epithelial cells while the thicker but looser
outer layer on top of the inner layer harbors the commensal
microflora (Johansson and Hansson 2016). Only at the top
of the crypts, there is some contact between the mucosal
immune cells from the colonic lamina propria and the
luminal content (Allaire et al. 2018). It is still unclear
whether this part of the colon is of significant importance
for immune signaling and tolerance. However the colonic
microbiota are producing large quantities of fermentation
products, such as vitamins, SCFAs, and secondary bile acids,
that can modulate the host’s metabolism and are essential
for human health (Hillman et al. 2017). For example, butyr-
ate, a major intestinal bacterial metabolite, is closely linked
to promoting the generation of Treg cells that induce toler-
ance for food antigens in infants (Newton, Priyadharshini,
and Turka 2016).
At early stages in life, the intestinal immune system is
immature and it develops rapidly in the early postnatal
period under the influence of bioactive components in
mother milk, and by encountering new dietary components
and microbiota (Macpherson, de Ag€uero, and Ganal-
Vonarburg 2017; Toscano et al. 2017). Breast milk compo-
nents such as growth factors, carbohydrates, cells, and
cytokines facilitate and expedite the maturation process
(Gila-Diaz et al. 2019; Parigi et al. 2015). The bioactive mol-
ecules in breast milk regulate the diversity of the microbiota
that impact immune maturation (Castanys-Mu~noz, Martin,
and Vazquez 2016; Conlon and Bird 2014; Gensollen et al.
2016) but they may also directly support development by
interacting with the immune system (Doare et al. 2018). In
the next sections, the different bioactive molecules in mother
milk that contribute to neonatal development are reviewed
in view of its possible impact on the infant’s gastrointestinal
immune system or gut barrier.
Bioactive components in human milk
It has become recognized in the past decade that human
milk is more than a source of nutrients. It is a source of
bioactive components as well, such as complex proteins, lip-
ids, and carbohydrates, which impact the infant’s metabol-
ism and immune system (Andreas, Kampmann, and
Mehring Le-Doare 2015). Bioactive components are defined
as “elements that show effects on biological processes or
substrates and thereby have an influence on body function
or condition and ultimately, health” (Schrezenmeir et al.
2000). Human milk contains several essential bioactive com-
ponents that regulate these processes. Some bioactive mole-
cules are produced and secreted by the mammary
epithelium, some are produced by the cells in breast milk,
while others are from maternal serum and transferred across
the mammary epithelium by receptor-mediated transport
(Vass et al. 2019). In response to the needs of the infant, the
presence and absence as well as quantities of these bioactive
components may vary in preterm and term delivery, or over
the course of lactation.
Growth factors
Human milk contains a large number of growth factors
which impact infant development and gastrointestinal mat-
uration. Epidermal growth factor (EGF) is one of these fac-
tors. It is important for intestinal and mucosal maturation
and for development of a well-established gut barrier func-
tion. EGF has been found in breast milk but also in amni-
otic fluid (Wagner, Taylor, and Johnson 2008). The
concentration of EGF in breast milk decreases during lacta-
tion, from approximately 100 ng/mL in colostrum to 50 ng/
mL in mature milk (Dvorak 2010). The concentration of
EGF in milk of mothers with extremely preterm neonates
(less than 28weeks) is 50–80% higher compared to that in
milk of mothers with full-term infants, which is directly cor-
related with an improved mucosal maturation in preterm
infants (Dvorak 2010; Dvorak et al. 2003). Insulin-like
growth factor-I (IGF-I), IGF-II, and IGF binding proteins
(IGFBP) are found in human milk too, which may play a
role in preventing oxidative stress-induced intestinal damage
(Baregamian et al. 2006; Blum and Baumrucker 2002). The
levels of IGF are highest in colostrum and decline over time
during lactation, which ranges from 20–50 ng/mL in colos-
trum and decrease to around 4 ng/mL in mature milk
(Hoeflich and Meyer 2017). In addition, high concentrations
of vascular endothelial growth factor (VEGF), which is
important for lymphatic vascular development (Secker and
Harvey 2015), are also present in breast milk. The concen-
tration of VEGF is highest in colostrum, reaching a concen-
tration of approximately 50 ng/mL, and lower in mature
milk at a concentration of 20 ng/mL (Loui et al. 2012;
Siafakas et al. 1999). Erythropoietin (Epo) is present in
human milk as well (Kling et al. 1998). The concentration of
Epo in human milk increases in time during lactation. It is
in the range of 4 to 5mU/mL in the first 1 to 2months and
increases to 100 to 150mU/mL by lactation (Semba and
Juul 2002). It enhances intestinal tight junctions and thereby
contributes to the development of barrier function and
gastrointestinal development and function, additionally, it is
associated with prevention of necrotizing enterocolitis
(Shiou et al. 2011).
Cells
A variety of cells are found in human milk too, including
leukocytes and stem cells, which are involved in immuno-
logical development and modulation (Witkowska-Zimny
and Kaminska-El-Hassan 2017). In colostrum, more than
106 cells/mL are found, but the numbers drop to approxi-
mately 103 cells/mL in the weeks after birth (Moles et al.
2018). The predominant leukocytes in human colostrum are
macrophages (40–50%), followed by polymorphonuclear
neutrophils (40–50%), and lymphocytes (5–10%) (Hassiotou
and Geddes 2015). T cells constitute the majority of lym-
phocytes (more than 80%) over B cells (Vieira Borba, Sharif,
and Shoenfeld 2018). The immune cells in human milk pro-
tect against pathogens in the lumen during the development
of the immune system of the newborn (Cacho and Lawrence
2017). In addition, stem cells have been found in mother
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milk (Cregan et al. 2007). Hosseini et al. confirmed the pres-
ence of stem cells in human milk and demonstrated that
they differentiate into neural cell lineages and thereby con-
tribute to gastrointestinal function and development
(Hosseini et al. 2014). Recently, Briere et al. compared breast
milk samples from mothers of preterm and term infants,
and found no significant differences in the numbers of
stem-like cells in these two groups, while the authors did
find differences in gene expression. Cell markers SOX2,
Nanog, CD90, and CD105 are up-regulated in the preterm
milk samples, and EpCAM and TJP1 were down-regulated
compared to full-term milk samples (Briere et al. 2017).
This might indicate different functions of stem cells in pre-
term and term milk. However, overall it is still largely
unknown to which processes stem cells in breast milk con-
tribute (Ninkina et al. 2019).
Besides human cells, breast milk is also a source of com-
mensal and beneficial bacteria, which shape the neonatal gut
microbiome and contribute to enhanced immune defense
and reduction of the incidence of infections (Jost et al. 2015;
Martın et al. 2005). Some studies demonstrate that breast
milk contains 103 to 104 CFU/mL bacteria. This is consider-
able when taking into account that infants by taking mother
milk consume approximately 105 to 107 bacteria every day
(Fernandez et al. 2013; Jeurink et al. 2013). Up to now,
more than 200 bacterial species have been isolated from
human milk. Most of these bacteria belong to
Staphylococcus, Streptococcus, Corynebacterium,
Propionibacterium, and Lactobacillus and Bifidobacterium
spp. (Collado et al. 2019; McGuire and McGuire 2017).
Some studies have investigated the potential relationship
between time postpartum and the composition of the
human milk microbiome which resulted in different conclu-
sions. Cabrera-Rubio et al. (2012) found that in colostrum,
the predominant bacteria are Weisella, Leuconostoc,
Staphylococcus, Streptococcus, and Lactococcus, whereas in 1-
and 6-months postpartum milk samples, the typical bacteria
of the oral cavity, i.e. Veillonella, Leptotrichia, and
Prevotella, are significantly increased. Khodayar-Pardo et al.
(2014) reported that Bifidobacterium spp. and Enterococcus
spp. counts increased during lactation as well. However,
Urbaniak et al. (Urbaniak et al. 2016) showed that time
postpartum has no effects on milk microbial composition.
In another study Boix-Amoros, Collado, and Mira (2016)
demonstrated that colostrum (5 days), transition (6–15 days),
and mature (after 15 days) milk show different bacterial
diversity, but no statistical significant differences were
observed between time points for any bacterial genus.
Therefore, based on current knowledge, it is hard if not
impossible to draw conclusions on changes in microbiota
composition in human milk during lactation.
Cytokines and chemokines
Cytokines and chemokines found in breast milk can pass
the intestinal barrier, protect and contribute to immune
development in the systemic circulation of the infant
(Dawod and Marshall 2019). Cytokines in human milk have
been shown to expedite immune maturation, to defend
against infections, and to prevent inflammation (Brenmoehl
et al. 2018). The most abundant cytokine in breast milk is
Transforming Growth Factor-b (TGF-b) (Sitarik et al. 2017).
TGF-b attenuates too strong immune responses and induces
tolerogenic signals, which may be instrumental in preventing
allergic diseases (Brenmoehl et al. 2018). However, the key
anti-inflammatory and immunoregulatory cytokine interleu-
kin-10 (IL-10), is found in very high concentrations during
the first 80 hours of lactation (Garofalo et al. 1995). It has
been suggested that IL-10 inhibits Th1 responses, contrib-
utes to the survival and expansion of B cells, and downregu-
lates major histocompatibility complex-II (MHC-II)
expression on monocytes (Dawod and Marshall 2019).
Another regulatory cytokine found in breast milk is IL-7.
This cytokine is involved in thymic development and sup-
ports T cell longevity, and thereby contributes to immuno-
logical development and adaptive immunity (Hossny et al.
2020). Also, proinflammatory cytokines are abundantly
present in mother milk. TNF-a, IL-6, IL-8, and interferon-c
(IFN-c) have all been found in human milk, and they gener-
ally decrease in concentration over the course of lactation
(Meki et al. 2003). The function of the proinflammatory
cytokines in human milk is still a subject of debate, but it
probably contributes to intestinal development and matur-
ation of immune cells in the infants gastrointestinal tract
(Brenmoehl et al. 2018).
Immunoglobulins
Immunoglobulins (Ig) are present in relatively high concen-
trations during early lactation and belong to the most
studied immune mediators in human milk (Cacho and
Lawrence 2017; Field 2005; Turfkruyer and Verhasselt 2015).
Infants are born with an immature adaptive immune system,
and they need to rely on antibodies from mother milk for
defense against infectious organisms (Andreas, Kampmann,
and Mehring Le-Doare 2015). The most predominant form
of immunoglobulin found in breast milk is secretory IgA
(SIgA) (L€onnerdal 2016). SIgA is the primary protective
agent in human milk. The SIgA antibodies in breast milk
are specific for enteric and respiratory pathogens such as
Vibrio cholerae, Escherichia coli, Giardia lamblia (Le Doare
and Kampmann 2014). SIgA shows a high concentration of
12mg/mL in colostrum and decreases to approximately
1mg/mL in mature milk (Goldman et al. 1982; Lawrence
and Lawrence 2004). While SIgA is the most abundant anti-
body in breast milk, it contains IgG and IgM too, which
both contribute to defenses and immunoregulation and
becomes more abundant in later lactation (Gao et al. 2012;
Rodrıguez-Camejo et al. 2018). IgG can facilitate antigen
uptake and is involved in the prevention of allergic and
autoimmune diseases (Palmeira and Carneiro-Sampaio
2016). Besides, pentameric IgM has been shown to neutral-
ize HIV-1 intracellularly and prevents transcytosis (Van De
Perre 2003).
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Antimicrobial proteins
A multifunctional iron-binding glycoprotein, i.e. lactoferrin
(LF), is present in mother milk and affects microbiota activ-
ity by protecting against infection through degradation of
gram-negative cell walls of pathogenic bacteria (Telang
2018). Lactoferrin is considered to be a so-called defensin
(Adamkin 2012). Defensins are a family of proteins that are
also produced by Paneth cells and reduce infection by delet-
ing pathogens without affecting commensal bacteria
(Chairatana and Nolan 2017). The concentration of LF is
typically highest in colostrum and reaches concentrations
between 5 and 6mg/mL. It decreases over time during lacta-
tion when the child is developing its immune system
(L€onnerdal 2016). Lactadherin, another glycoprotein found
in human milk, known as milk fat globule-epidermal growth
factor 8 (MFG-E8) as well, has been shown to have specific
anti-viral functions and prevents rotaviral infection in the
newborn (Sabha et al. 2018). More than that, it prevents
intestinal inflammation by enhancing the phagocytosis of
apoptotic cells (Aziz et al. 2017). In addition, a recent study
showed that lactadherin can prevent necrotizing enterocolitis
(NEC) by enhancing intestinal barrier integrity (Sabha et al.
2018). Milk fat globules (MFGs) are milk lipids present in
the form of dispersed droplets (Martini, Salari, and
Altomonte 2016). Several bioactive glycoproteins have been
characterized in MFGs, which contain mucin 1 (MUC1) and
mucin 4 (MUC4) (Hamosh et al. 1999). Both MUC1 and
MUC4 inhibit the invasion of Salmonella enterica serovar
typhimurium in intestinal epithelial cells (Liu et al. 2012).
Human milk oligosaccharides
One of the most important bioactive components of mother
milk is the human milk oligosaccharides (hMOs). The con-
centration of hMOs ranges from 20 to 25 g/L in colostrum
and 5 to 20 g/L in mature milk, which makes them the
third-largest solid component in human milk (Bode 2012).
hMOs are unique to humans and are not found in the same
variety and composition in other mammals (Bode 2012).
Several studies show that hMOs provide numerous health-
promoting effects (Cheng et al. 2019; Doare et al. 2018;
Kong et al. 2019). Before critically reviewing possible benefi-
cial effects for gastrointestinal development and health, we
review the structure and composition of hMOs.
HMO structures and compositions
HMOs are composed of five monomers: D-glucose (Glc), D-
galactose (Gal), N-acetylglucosamine (GlcNAc), L-fucose
(Fuc), and sialic acid (NeuAc) (Figure 2A). All hMOs are
synthesized from lactose (Galb1-4Glc), which can be
extended by the addition of b1-3 or b1-6 linked lacto-N-
biose (Galb1-3GlcNAc-, LNB, type 1 chain) or N-acetyllac-
tosamine (Galb1-4GlcNAc-, LacNAc, type 2 chain). The
addition of LNB terminates the chain, while type 2 chain
LacNAc can be further extended. The b1-6 linkage creates
branched structures, which are designated as iso-hMO; the
linear structures without branches are called para-hMO
(Figure 2B). The hMO backbone can be either sialylated or
fucosylated, and in the case of the shortest hMOs this forms
trisaccharides such as 20-fucosyllactose (20-FL), 3- fucosyllac-
tose (3-FL), 30-sialyllactose (30-SL) and 60-sialyllactose (60-
SL) (Figure 2C). The lactose core can also be extended with
b1-3, b1-4 and b1-6 galactosyl residues and form galactosyl-
lactoses (GL) (Figure 2D), which are typically present in
human colostrum rather than in mature milk (Kulinich and
Liu 2016). Elongated hMOs can be fucosylated in a1-2, a1-3
or a1-4 linkages and/or sialylated in a2-3 or a2-6 linkage to
form a variety of structural isomers as well (Figure 2E).
hMOs are synthesized in the mammary gland. To date,
approximately 200 different hMOs have been discovered and
characterized (Thurl et al. 2017). The molecular structures
and ratios vary among individuals and is depending on the
expression of the a1-2- fucosyltransferase (FUT2) and a1-3/
4-fucosyltransferase (FUT3) in lactocytes (Bode 2019). The
hMOs profile is determined by Secretor (Se) and Lewis (Le)
blood group genes (Elwakiel et al. 2018). The enzymes
FUT2 and FUT3 are encoded by Se gene and Le gene,
respectively. Individuals with an active Se locus are called
secretors, and individuals with an active Le locus are classi-
fied as Lewis positive. Based on the expression of Se and Le
genes, human milk can be divided into four groups: Le-posi-
tive Secretors (FUT 2 active, FUT3 active, SeþLeþ), Le-
negative Secretors (FUT 2 active, FUT3 inactive, SeþLe),
Le-positive non-Secretors (FUT2 inactive, FUT3 active,
SeLeþ), and Le-negative non-Secretors (FUT2 inactive,
FUT3 inactive, SeLe). FUT2 is responsible for connecting
Fuc to terminal Gal through a1–2 linkages, and 20-FL is the
most abundant hMO in secretor women (Egge, Dell, and
Von Nicolai 1983; Thurl et al. 2010). In contrast, the milk
of non-secretor women does not contain a1-2-fucosylated
hMOs, i.e. 20-FL. FUT3 is responsible for connecting Fuc to
GlcNAc in type 1 chains through an a1-4 linkage on type 1
chains, and as a result Le-negative woman do not have these
specific a1-4-fucosylated hMOs, such as lacto-N-fucopen-
taose II (LNFP II) (Johnson and Watkins 1992).
Beneficial effects of human milk oligosaccharides
In this section, we focus on current knowledge of hMO
functions. The evidence for these functions will be critically
reviewed. Figure 3 illustrates some of the discussed effects.
We critically review the evidence for the effects of hMOs on
gut microbiota composition, immune defense, intestinal epi-
thelial cells, and the gastrointestinal barrier. We also discuss
the addition of hMOs to infant formula as well as the chal-
lenges for further studies to investigate the effects of hMOs
and creation of optimal formulations for adding to
infant formula.
hMOs and microbiota
hMOs are considered to have a strong impact on coloniza-
tion of the intestine by bacteria that are essential for health
(Jost et al. 2015). In early life, the intestine is colonized by
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1014 bacterial cells (Hillman et al. 2017). The first year of
life is critical for intestinal microbiome establishment, and
infant diet is one of the most important factors for gut
microbiome development (Tamburini et al. 2016). As many
hMOs resist the gastric acidity and the host enzyme’s
hydrolysis processes in the small intestine, high concentra-
tions of hMO can reach both the small and large intestine,
and modulate the activity and composition of the resident
microbiota (Kirmiz et al. 2018; van den Elsen et al. 2019).
hMOs support beneficial bacteria
hMOs are specifically known to support the growth of bene-
ficial microorganisms (Figure 3A), especially Bifidobacterium
Figure 2. Structures of hMOs. (A) Building blocks and structural blueprint of hMOs. (B) Lactose can be elongated by addition of either lacto-N-biose (type I) or N-
acetyllactosamine (type II) disaccharides. The addition of a b1-6 linkage produces branched structures (iso-hMO); the b1-3 linkage leads to linear structures (para-
hMO). (C) Lactose is fucosylated or sialylated through different linkages to generate trisaccharides. (D) Galactosyl residues are linked to lactose through b1-3, b1-4-
and b1-6 linkages to form galactosyllactoses. (E) Elongated type I or II chains can be fucosylated or sialylated in different linkages to form a variety of struc-
tural isomers.
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species, which is a dominant species in breast-fed infants
(Kirmiz et al. 2018). One of the Bifidobacterium species,
Bifidobacterium longum supsp. infantis (B. longum supsp.
infantis) grows well when cultured with pooled hMOs iso-
lated from human milk as the sole carbohydrate source. In
those cultures, all of the hMOs are consumed entirely by
this Bifidobacterium strain. The concentrations of 20-FL, 3-
FL, LDFT, LNT, LNnT, LNFP I, LNFP II, LNFP III,
LNDFH I, and LNDFH II all rapidly decreased when the
cells entered the logarithmic phase (Sadaki Asakuma et al.
2011). In the same in vitro study, it was found that
Bifidobacterium longum subsp. longum (B. longum subsp.
longum) , and Bifidobacterium breve (B.breve) are only able
to consume lacto-N-tetraose (LNT) (Asakuma et al. 2011).
This study demonstrates that multiple bifidobacteria species
can consume hMOs but that not all Bifidobacterium species
can use hMOs as only carbohydrate sources (Thomson,
Medina, and Garrido 2018).
Bacteria can degrade hMOs using both intracellular and
extracellular glycoside hydrolases (Garrido et al. 2015;
Kitaoka 2012). Intracellular degradation, which can be done
by B. infantis, B. breve, and B. longum subsp. longum, is
based on the uptake of intact hMOs inside the bacteria. The
uptake is accomplished by several Solute Binding Proteins
(SBPs). After being transported into the bacteria, the intra-
cellular glycosyl hydrolases (GHs) degrade the hMOs and
release monosaccharides in the cytoplasm instead of outside
the bacteria (Garrido et al. 2011, 2015). The extracellular
degradation is different and found in, for example,
Bifidobacterium bifidum (B. bifidum). In contrast to B.
infantis, B. bifidum relies on the membrane-bounded extra-
cellular GHs, which show similar enzymatic affinities for
hMOs as in B. infantis (Kitaoka 2012). Gotoh et al. showed
that the extracellular hMO degradation of B. bifidum results
in the production of sugars and thereby stimulate the
growth of other species that can utilize these carbohydrates
as source of energy (Gotoh et al. 2018).hMOs do not only
support the growth of bacteria, they can enhance binding of
commensal bacteria to epithelial cells, and thereby support
microbiota colonization in infants. For example, Kavanaugh
et al. demonstrated that a mixture of 30-SL and 60-SL
increase B. longum subsp. infantis ATCC 15697 adhesion to
human HT-29 intestinal cells in vitro (Kavanaugh et al.
2013). Wickramasinghe et al. found that an hMO mixture
Figure 3. Overview of known functions of hMOs in the intestine. (A) Support the growth and colonization of beneficial bacteria. (B) Antimicrobial and antiviral
effects by serving as decoy for pathogens and/or inhibit the growth of pathogens. (C) Exert a direct influence on intestinal epithelial cells by enhancing barrier func-
tion. (D) Immunomodulatory effects. (E) Effects on intestinal barrier function.
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enhanced the anti-inflammatory effects of bifidobacteria on
intestinal cells in vitro (Wickramasinghe et al. 2015). Besides
the direct influence of hMOs on bifidobacteria, it can modu-
late the growth and fermentation activity of other bacterial
species (Salli et al. 2019; Schwab et al. 2017). Salli et al.
found that 20-FL promoted the growth of bifidobacteria, and
significantly increased production of SCFAs as well as of lac-
tic acid in a human study (Salli et al. 2019). Schwab et al.
investigated the interaction between bifidobacteria and
Eubacterium hallii (E. hallii), one of the first butyrate
producers in the infant’s gut in a human study. They dem-
onstrate that E. hallii consumes acetate, lactate and 1,2-pro-
panediol, which are the hMOs fermentation products of
bifidobacteria, and subsequently produces the SCFAs butyr-
ate and propionate, thereby supporting gut barrier function
and the immune system (Schwab et al. 2017).
hMOs prevent pathogen infection
hMOs can reduce pathogen infection in infants in several
ways (Figure 3B). They can do so by serving as soluble decoy
receptors or by inhibiting the growth of pathogens (Townsend
2019). Many viruses and pathogens need to attach to the intes-
tinal epithelial glycocalyx to colonize or invade the host (Kong
et al. 2019). By structural resemblance to the glycocalyx layer,
hMOs can bind to pathogens and serve as antiadhesive antimi-
crobials, and prevent microbial infections (Patel and Kim
2018). For example, Campylobacter jejuni (C. jejuni), which is
one of the most common causes of bacterial diarrhea and
infant mortality, can bind to a1-2-fucosylated hMOs in vitro,
such as 20-FL, and reduce its binding and infection of intestinal
cells (Ruiz-Palacios et al. 2003). In an in vitro study, Jantscher-
Krenn et al. found that LNT significantly reduced the attach-
ment and cytotoxicity of the protozoan parasite Entamoeba
histolytica (E. histolytica) to intestinal epithelial cells (Jantscher-
Krenn, Lauwaet, et al. 2012). Interestingly, although 20-FL can
reduce host-adhesion and infection of C. jejuni, it does not
affect E. histolytica attachment and cytotoxicity, which indicates
that the decoy effect of hMOs is species dependent.
Recent studies have shown that hMOs also exhibit anti-
microbial and antibiofilm effects against Group B
Streptococcus (GBS), which cause invasive infections in new-
borns (Ackerman et al. 2017; Lin et al. 2017). In these stud-
ies, hMOs isolated from human milk significantly inhibited
the growth of GBS up to 89% and inhibited biofilm forma-
tion up to 90%. Ackerman et al. found that hMOs isolated
from human milk possessed significant antimicrobial activity
against Acinetobacter baumannii (A. baumannii) and could
inhibit adhesion up to 11%. Moreover, it could inhibit bio-
film formation of Staphylococcus aureus (S. aureus) up to
60% (Ackerman et al. 2018).
hMOs show direct modulatory effects on intestinal
epithelial cells
hMOs do not only have a strong impact on microbes, they
can directly influence intestinal epithelial cells (Figure 3C).
An in vitro study by Kuntz et al. showed that both acidic
and neutral hMOs isolated from human milk had inhibitory
effects on intestinal epithelial cells proliferation under
homeostatic conditions (Kuntz, Rudloff, and Kunz 2008).
However, Wang et al. showed in an animal model that
pooled hMOs could increase the proliferation of crypt cells
under inflammatory conditions which might protect against
necrotizing enterocolitis (Wang et al. 2019). These studies
indicate that hMOs might have different functions depend-
ing on the nature of the inflammatory conditions. Holscher
et al. found that in vitro, 60-SL, 20-FL, and LNnT all could
inhibit proliferation of HT-29 and Caco-2Bbe cells, while
they enhanced differentiation of HT-29 and Caco-2Bbe cells
(Holscher, Bode, and Tappenden 2017). These results sug-
gest that hMOs may have a specific role in the maturation
of the gastrointestinal tract. The maturation of intestinal epi-
thelium requires a shift from sialylation to fucosylation
(Lenoir et al. 1995), and hMOs can modulate intestinal epi-
thelial cells through modification of the intestinal glycome
(Kavanaugh et al. 2015). There are additional studies show-
ing that hMOs can alter the structure of the intestinal epi-
thelial cell glycocalyx layer (Angeloni et al. 2004; Kong et al.
2019). Angeloni et al. found that in vitro, 30-SL lowered
gene expression of the sialyltransferases ST3Gal1, ST3Gal2,
and ST3Gal4, which resulted in reduction in a2-3-, a2-6-sia-
lylation on cell surface glycans of Caco2 cells, and as a con-
sequence reduced the enteropathogenic Escherichia coli
(EPEC) adherence to about 50% (Angeloni et al. 2004).
Kong et al. showed 20-FL as well as 3-FL significantly
increased the thickness of the glycocalyx layer in vitro
(Kong et al. 2019). These observations suggest that hMOs
stimulate glycocalyx development in a structure-depend-
ent manner.
Immunomodulatory effects of hMOs
Although the influence of hMOs on microbiota may affect
the immune system indirectly, studies suggest that hMOs
can modulate immune function in different ways as well
(Figure 3D). An ex vivo study by He et al. shows that hMOs
derived from pooled human colostrum can attenuate patho-
gen-associated molecular pattern (PAMP) induced produc-
tion of inflammatory cytokines such as IL-8 in the
immature intestinal mucosa (He et al. 2014). In addition, an
elevation of levels of cytokines such as MIP-1-d involved in
tissue repair and homeostasis in immature human intestinal
mucosa was observed. Such an hMO effect might help to
promote the maturation of the intestinal mucosal immune
system (He et al. 2014). He et al. also demonstrated in vitro
that 20-FL could attenuate type 1 pili pathogens derived lipo-
polysaccharide (LPS) induced IL-8 production in T84 and
H4 cells by decreasing CD14 induction (He et al. 2016). The
hMO disialyllacto-N-tetraose (DSLNT) was shown to sup-
press necrotizing enterocolitis-like inflammation in neonatal
rats and is therefore identified as an immunomodulating
and immune activation attenuating hMO (Jantscher-Krenn,
Zherebtsov, et al. 2012). Besides that, hMOs have been
shown to have immune-stimulating or maturation promot-
ing properties. Kurakevich et al. (2013) found that 30-SL
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stimulates MLN CD11cþ dendritic cells and increases TNF-
a, TGF-b1, IL-12, and IFN-c production in an animal
model. Those cytokines typically induce increased Th1 and
Th17 cell frequencies. Moreover, Thomas et al. (2003) dem-
onstrated in vivo that LNFP III induces strong Th2
responses and promotes dendritic cell 2 (DC2) maturation.
It is currently unknown which receptors and signaling
pathways are involved in transducing hMO-mediated effects;
however, some studies suggest that hMOs can interact with
pattern recognition receptors (PRRs) and interfere with
immune processes. It has been found that the immunomo-
dulatory effects of hMOs can be induced via Toll-like recep-
tors (TLRs), which are a family of PRRs. In an in vitro
study, Asakuma et al. found that 30-SL, 60-SL, and 60-GL
enhanced both TLR2 and TLR4 expression, while LNFP I
only increased the gene expression of TLR4 (Asakuma et al.
2010). 3-FL and LNT2 have been observed to activate TLRs.
In an in vitro study by Cheng et al. 3-FL could activate
TLR2, while LNT2 could activate all TLRs and induced both
IL-10 and TNFa in THP1 macrophages. 60-SL showed a syn-
ergistic effect on ssRNA40-induced TLR8 activation (Cheng
et al. 2019). Beside activation effects, hMOs show inhibiting
effects on TLRs signaling as well. He et al. (2014) found ex
vivo that 30-GL, 40-GL, and 60-GL are able to attenuate the
inflammatory response through TLR3. Cheng et al. demon-
strated that 20-FL, 60-SL, and LNnT inhibit TLR5 and 7,
while 3-FL inhibit TLR5, 7, and 8 in vitro (Cheng et al.
2019). This illustrates the complexity by which mixtures of
hMOs modulate immune responses and how variations in
composition can lead to different types of immune modula-
tion opening novel venues to prevent diseases in infants on
infant formula.
Galectins are b-galactoside binding proteins that are
involved in many immune responses (Vasta 2012). Some
hMOs contain b1-3- or b1-4-linked D-galactose at the non-
reducing end, which can be the potential target for galectin-
mediated interactions. The binding affinities of a library of
31 free hMOs with galectins Gal-1, Gal-3, and Gal-7 have
been studied by catch-and-release electrospray ionization
mass spectrometry (CaR-ESI-MS). It was shown that hMOs
have high binding affinity to galectins (El-Hawiet et al.
2017). Whether hMOs are able to modulate galectin-medi-
ated immune responses still needs further investigation, but
the CaR-ESI-MS method provided another possible
approach for rapid screening of the interaction between free
hMOs and receptors to find the potential hMO receptors.
Since around 1% of the hMOs can reach the systemic cir-
culation, it is plausible that hMOs not only impact the intes-
tinal tract but also influence development of other organs
(Plaza-Dıaz, Fontana, and Gil 2018). An in vitro study
showed that mixtures of hMOs isolated from pooled human
milk significantly reduced uropathogenic Escherichia coli
(UPEC) internalization in bladder epithelial cells. It attenu-
ated the cytotoxic and proinflammatory effects induced by
UPEC as well (Lin et al. 2014). Furthermore, Duska-
McEwen et al. showed in vitro that hMOs can enhance
innate immunity to airway infections (Duska-McEwen et al.
2014). 20-FL could decrease respiratory syncytial virus (RSV)
viral load while 60-SL and LNnT were able to decrease influ-
enza viral load in airway epithelial cells (Duska-McEwen
et al. 2014). They also showed that 2’FL could attenuate
RSV induced inflammatory cytokines IL-8 and TNF-a pro-
duction in airway epithelial cells, while 60-SL down-regulated
TNF-a in RSV infected peripheral blood mononuclear cells
(PBMCs) (Duska-McEwen et al. 2014). This again illustrates
the specificity of different type of hMOs for health benefits.
Hmos enhance intestinal barrier function
The primary function of the gastrointestinal tract is to digest
and absorb nutrients, while at the same time it has to act as
a barrier and protect against toxic agents or potential patho-
genic intruders (Figueroa-Lozano and de Vos 2019).
However, the intestinal tract of neonates is functionally
immature at birth (Lewis et al. 2017). hMOs support intes-
tinal barrier function both through indirectly influencing
microbiota composition and directly by modulating intes-
tinal cells (Figure 3E). An animal study by Fukuda et al.
shows that fermentation of hMOs by bifidobacteria leads to
acetate formation, which can enhance gut barrier function
and protect the host against lethal infection induced by
enterohemorrhagic Escherichia coli O157:H7 (Fukuda et al.
2011). Fermentation products of hMOs secreted by the bifi-
dobacterial strain B.infantis are reported to enhance epithe-
lial cell barrier function. Guo et al. showed that B. infantis
conditioned media (BCM) protects Caco2 cells against IL-1b
stimulation through signaling through the NF-jB pathway
in an in vitro study (Guo et al. 2017). BCM up-regulated
protein expression of claudin-1 and occludin, which are
responsible for the preservation of intestinal barrier integrity
(Lewis et al. 2017). Therefore, hMOs can support intestinal
barrier function by promoting the growth and supporting
production of fermentation products by Bifidobacterium spe-
cies. Chichlowski et al. found in vitro that B. infantis
ATCC15697 grown on mixtures of hMOs isolated from
mother milk had a significantly higher capacity to adhere to
HT-29 cells, which induced higher expression of tight junc-
tion proteins such as occludin and junctional adhesion mol-
ecule (JAM-A) in gut epithelial cells (Chichlowski et al.
2012). Wu et al. demonstrated that hMOs isolated from
pooled milk could increase mucin expression in intestinal
cells both in vitro, ex vivo, and in vivo (Wu et al. 2018).
They found that administration by oral gavage of hMOs to
mouse pups increased MUC2 protein levels and decreased
the permeability of the intestine to macromolecular dextran.
Their study also showed that hMOs in human milk can
induce MUC2 gene expression and decrease dextran
permeability during an enterohemorrhagic Escherichia coli
O157:H7 challenge in intestine epithelial cells (Wu
et al. 2018).
hMOs in infant formula and regulatory considerations
Although the World Health Organization (WHO) recom-
mends six months of exclusive breastfeeding after birth, this
period is rarely fulfilled as breastfeeding is not always
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possible. For a variety of reasons, around 70% of the infants
cannot be solely fed with breast milk (Martin, Ling, and
Blackburn 2016). These infants receive cow milk-derived
infant formulas, which attempts to mimic the nutritional
composition of breast milk as closely as possible (Akkerman,
Faas, and de Vos 2019). Despite many beneficial effects of
hMOs, only 20-FL and LNnT are currently used in infant
formula, mainly because hMOs are complex molecules and
because synthesis of hMOs is still challenging and expensive
(Akkerman, Faas, and de Vos 2019; Vandenplas et al. 2018).
Non-digestible fibers such as galacto-oligosaccharides (GOS)
and inulin-type fructans are nowadays often added to com-
mercially available infant formulas to substitute some of the
hMO’s beneficial effects (Akkerman, Faas, and de Vos
2019). However, recent improvements in production proc-
esses make it possible to produce some smaller molecular
weight hMO molecules in sufficient quantities to allow
application in infant formulas (Vandenplas et al. 2018). The
commercially available hMO analogs are not isolated from
human milk but are the fermentation products of genetically
engineered microorganisms, which include strains of E. coli
and yeast (Sprenger, Baumg€artner, and Albermann 2017).
Although hMOs are natural carbohydrates that are being
recognized as safe for a long time, the use of chemical- or
biotechnology-based processes to produce synthesized hMOs
makes it necessary to evaluate the safety of the production
procedure as well as the novel compounds through a series
of registration processes (Bode et al. 2016).
Nowadays, the European Union (EU) considers 20-FL
and LNnT, two produced hMOs, as authorized novel foods
that can be used in infant formulas (Commission
Implemented Regulation (EU) 2017/2470). On 29 June 2015,
the European Food Safety Authority (EFSA) concluded that
a concentration up to 1.2 g/L of 20-FL, alone or in combin-
ation with LNnT at a ratio of 2:1, is safe for infants when
added to infant and follow-on formula (EFSA NDA Panel
2015a). In the same year, the Panel concluded that LNnT
and 20-FL are considered as safe as food supplements for
1–3 year old toddlers. Intake of these hMOs may not exceed
0.6 g of LNnT and 1.2 g of 20-FL (alone or in combination)
per day. For 4-18 years old children, 1.5 g of LNnT and 3 g
of 20-FL (alone or in combination) per day is recommended
(EFSA NDA Panel 2015b). The USA’s Food and Drug
Administration (FDA) considers three hMOs to be
Generally Regarded as Safe (GRAS). Those hMOs are 20-FL
(GRAS notice no 546/571/650/735), LNnT (GRAS notice no
659), as well as 30-SL (GRAS notice no 766). Through scien-
tific procedures, the FDA considers 20-FL to be GRAS at a
maximum use level of 2.4 g/L in reconstituted formula;
LNnT is GRAS at a maximum use level of 0.6 g/L in infant
formula and 3 g/serving in follow-up formulas; and 30-SL is
GRAS at a level up to 0.23 g/L in infant formula and 3.1 g/
serving in 12–24months old toddler foods. As a conse-
quence of these approvals, there are now hMOs in infant
formulas on the market containing 20-FL in the USA and 20-
FL and LNnT in Europe since 2016 (Austin et al. 2018;
Vandenplas et al. 2018).
The safety assessments of more synthesized hMOs are
currently ongoing. Lately, Pitt et al. conducted in vitro and
in vivo safety assessment experiments of genetically modified
E. coli K12 strain produced 3-FL and concluded that 3-FL is
safe as a nutritional ingredient in foods (Pitt et al. 2019).
More studies on the safety evaluation of hMOs are expected
to follow soon, making it possible to consider more hMOs
as novel foods in products in the near future.
Concluding remarks and future considerations
The importance of hMOs in human milk and their benefi-
cial effects on the infant are unequivocal, which have been
previously studied in vitro (Cheng et al. 2019), ex vivo (He
et al. 2014), in vivo (Wu et al. 2018), as well as in human
studies (Salli et al. 2019). However, many questions about
hMO synthesis, metabolism, and functions are still
unanswered, and to date, there is little evidence available to
support the beneficial function of individual hMOs. One of
the major roadblocks remains the limited availability of syn-
thesized hMOs to confirm their health in neonates. The lim-
ited resources and the high price of the synthesized hMOs
make that scientists, and formula companies have to make
decisions on which individual hMOs to study. At this
moment, only some tri- and tetrasaccharides can be pro-
duced in kilogram quantities to study their functions, but
the identification of benefits of more complex and/or the
mixture of different hMOs still need more research efforts.
The efforts are urgently needed as many studies have shown
that health benefits of hMOs are very specific for specific
hMO types and many more benefits are to be expected if
mixtures with confirmed bioactivities can be applied in
infant formula.
While the beneficial effects of mixtures of hMOs have
been broadly proven, it is crucial in future efforts to identify
the composition of the hMOs in the mixtures. As outlined
in our review the composition varies considerably between
breast milk from mothers with premature or mature infant
and over the course of lactation. Also, non-secretor women
have a different hMO composition than milk from secretor
mothers. During recent years it has been shown by us and
others that individual hMOs have different effects and that
the final outcome of a specific health benefit dependents on
the composition of the mixture and or quantity of individual
hMOs (Cheng et al. 2019; Kong et al. 2019; Salli et al. 2019).
Side-by-side comparison of hMO composition of the mix-
tures will contribute to a better understanding of sometimes
contradictory results and may lead to a better understanding
of the impact of specific hMOs for infant health.
Another change in experimental design which might lead
to a better understanding of health benefits of hMOs is
studying the impact of individual or well-defined mixtures
of hMOs on human intestine cells. In particular, there is a
need to understand whether different structures of hMOs
modulate different types of cells such as epithelial cells,
Paneth or goblet cells, in a structure-dependent manner.
This knowledge is urgently needed to propose formulations
of mixtures that support barrier function in e.g. premature
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babies with enhanced risk for development of NEC. It is
also essential to understand which signaling pathways of dif-
ferent hMOs are involved in different cells to gain more
insight in mechanisms involved and therewith to support
acceptance of health benefits of hMOs. Besides, the impact
on microbiota of infants requires more study. Interestingly
it was recently shown that 20-FL, which currently is
approved for and applied in infant formula, is poorly fer-
mentable by 2-12weeks baby microbiota, and had lower
production of acetate and lactate compared with lactose or
GOS (Salli et al. 2019). What this implies for support of
microbiota in infants requires further investigation but it
seems that most effects of 20-FL relate to direct effects on
intestinal cells rather than on support of microbiota (Kong
et al. 2019; Salli et al. 2019).
It has been shown that infant microbiota varies consider-
ably in composition and diversity depending on the age of
the infant (Chong, Bloomfield, and O’Sullivan 2018;
Dominguez-Bello et al. 2010; Hill et al. 2017; Mueller et al.
2015). Especially in the first 8 weeks infants do not have the
full enzymatic ability to ferment all hMOs (Mountzouris,
McCartney, and Gibson 2002; Salli et al. 2019). Blood
group-specific differences were found too (Ewald and
Sumner 2018; M€akivuokko et al. 2012). This is probably due
to the fact that the mucus layer in the intestine has blood
group-specific oligosaccharide epitopes (Tailford et al. 2015).
As microbiota use mucus as substrate, this probably predis-
poses to blood group specific microbiota and utilization of
hMOs. To gain more insight in efficacy of hMO on micro-
biota development and the colonization process it is needed
to study the impact on microbiota of different age classes
and blood groups. Also, there are indications that fermenta-
tion is different in healthy and diseased children
(Ladirat 2014).
Understanding how and which hMOs are responsible for
specific effects not only contributes to future design of
hMO-containing infant formulas, in addition, it might pro-
vide new ways to explore the function of hMOs as therapeu-
tics. For example, as members of the “ESKAPE” group of
pathogens, the leading cause of multidrug-resistant (MDR)
nosocomial infections throughout the world, A. baumannii
and S. aureus both show methicillin-resistance (Santajit and
Indrawattana 2016). The antimicrobial and antibiofilm prop-
erties of hMOs on A. baumannii and S. aureus could poten-
tially be used as new therapeutics to treat or prevent
infectious disease, which provides a new way to manage
drug-resistant bacteria.
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